Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Patients From bedside to breakthroughs: Reimagining the human experie... Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.
Patients Reshaping the future of patient-centric drug development Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.
Patients Moving from patient centricity to patient partnership The desire for patients to be active partners in research challenges how organisations approach patient engagement.
R&D Parexel: Flawless execution, policy shifts & patient-centric... Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.
Patients Patient engagement drives clinical and commercial success Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
